Thursday, September 7, 2023

Multiple Focal Choroidal Excavations in Association with Protein Rich Diet

 

Introduction

Choroidal excavation is a novel entity that is diagnosed with optical coherence tomography (OCT). In 1959, Klien, et al. [1] first described a concave-shaped chorioretinal abnormality with undifferentiated choriocapillaris and retinal pigment epithelium. Then in 2006, Jampol [2] defined similar changes with OCT and first used the term of focal choroidal excavation (FCE). In 2011, Margolis, et al. [3] described two FCE patterns, based on the shape of the lesions: nonconforming, if the photoreceptors are detached from retina pigment epithelium (RPE) and conforming, when the RPE follows the photoreceptor layer without any optically clear space between the outer retina and RPE. These two forms are also thought to convert to each other during the clinical process of the disease [4]. Although it is known to be mostly idiopathic, its relationship with central serous chorioretinopathy, choroidal neovascular membrane and inflammatory diseases such as multiple evanescent white dot syndrome and Vogt Koyanagi Harada disease has been reported [5]. In this report, we present a patient with multiple focal choroidal excavation following protein-rich diet.

Case

21-year-old male patient applied with blurred vision in his right eye since one week. He was on a protein rich diet since he was doing bodybuilding and had been using approximately 2g/kg/day protein powder since 3 months. His best corrected visual acuity was 0,6 in his right eye (RE) and 0,9 in his left eye (LE). There was no refractive disorder. Slit lamp examination and intraocular pressure were normal. Fundus examination revealed cavitary lesions in the macula of the RE (Figure 1a) and pigmentary changes above the macula of the LE (Figure 1b). OCT showed multiple conforming (Figure 2a) and non-conforming (Figure 2b) type of focal choroidal excavations with small retinal pigment epithelium detachments in the right eye and a small retinal pigment epithelium detachment in the left eye (Figure 2c). When evaluated with fundus autofluorescence (FAF), there have been hypo and hyperautofluorescent areas in the macula of the right eye in accordance with the pigmentary changes (Figure 3a) and hypoautofluorescent area above the macula of the left eye (Figure 3b). Fundus fluorescein angiography showed multiple hyperfluorescent window defects in the macula of the RE and hyperfluorecence consistent with window defect above macula of the LE. There was no ischemia, leakage, macular edema and all vascular structures were normal . Protein powder stopped and the patient was examined 6 months after the diagnosis. No changes in the findings were detected.


Read more about this article : https://lupinepublishers.com/ophthalmology-journal/fulltext/multiple-focal-choroidal-excavations-in-association-with-protein-rich-diet.ID.000158.php

Read More About Lupine Google Scholar:    https://scholar.google.com/citations?view_op=view_citation&hl=en&user=T4c9RDkAAAAJ&citation_for_view=T4c9RDkAAAAJ:blknAaTinKkC


Friday, August 25, 2023

GLS-1027 to Treat Anterior Uveitis in a Cavalier King Charles Spaniel Dog

 
Abstract
Non-infectious, autoimmune anterior uveitis is a significant cause of ocular disease in both dogs, horses, and humans with the potential for significant vision loss. The mainstay of treatment is topical and/or systemic corticosteroids, however, animals, similar to humans, are not uncommonly resistant to therapy. Additionally, prolonged corticosteroid treatment may cause systemic and ocular toxicity. We describe here a case of steroid-resistant uveitis successfully treated with GLS-1027, an immunomodulatory compound that inhibits Th17 maturation and release of multiple inflammatory cytokines involved in the pathogenesis of uveitis. GLS-1027 may provide an alternative as a steroid-sparing therapeutic option.

Introduction
Non-infectious, anterior uveitis is a significant cause of ocular disease in dogs, horses, humans, and other species that has the potential to lead to vision loss and blindness. While the disease is most commonly considered as autoimmune for humans and the most common etiology in dogs [1,2] infectious disease neoplastic etiologies must also be considered [2,3]. In all species, the primary goal of treatment is sight preservation with secondary goals to limit pain, discomfort, photophobia, and in dogs minimizing secondary sequelae such as posterior synechia [3]. In animals, topical corticosteroid treatment combined with topical mydriatics with or without the use of systemic anti-inflammatory medications represents the standard of care for anterior uveitis [2,4]. While immunosuppressives are considered the standard for steroidresistant disease in humans [5], these are seldom used in animals due to toxicity and cost. Studies in animals have reported that approximately 1-35% of the total topical corticosteroid dose is systemically absorbed, [4] and may result in systemic side effects, including endocrinopathies [3]. Steroid-induced ocular pathology, including the development of glaucoma, cataract formation, and keratopathy are not uncommon in dogs with prolonged corticosteroid use [4] with a similar side effect profile for humans. Therefore, a safe and effective alternative to corticosteroid treatment for chronic recurrent idiopathic uveitis is warranted. Autoimmune uveitis in humans [6] and horses [7,8] has been attributed to Th17 mediated pathology with a complex interplay between a number of inflammatory cytokines including TNFα and IL-6. GLS-1027, [S,R]-3-phenyl-4,5-dihydro-isoxazoleacetic acid, is a small molecule compound with anti-inflammatory activity currently in clinical development. GLS-1027 is a potent inhibitor of lipopolysaccharide (LPS)-induced inflammation characterized by normalization of levels of the cytokines tumor necrosis factor (TNFα), interleukin (IL) 1β, and IL-6 both in vitro and in murine animal models [9-12]. Additional unpublished data has shown that GLS-1027 inhibits IL-17 and IL-23 mediated activation and downregulates Th17 T cells.

In this paper, we describe a case report of the use of GLS-1027 to treat canine uveitis.

 

Read More About Lupine Google Scholar: https://scholar.google.com/citations?view_op=view_citation&hl=en&user=T4c9RDkAAAAJ&citation_for_view=T4c9RDkAAAAJ:JV2RwH3_ST0C


Tuesday, August 15, 2023

Cauchy Modeling as a New Trend in Research of Fullerene- Type Nanomaterials

 

Abstract

In the work, based on the analysis of heat and gas with acoustic phonons by fullerene, the physical criterion Cauchy is the kind of thermal strength before spring strain, which is caused by the nanotube fullerene

Keywords: Thermal Conductivity; Fullerene; Optimization; Numbers Similarity Numbers

Introduction

Studies of the thermal conductivity of structured nano systems draw attention to the fact that in micro- and nanoelectronics the urgent task of heat dissipation released during the operation of electrical elements [1-6]. So, in the process of electrical switching of the element energy is consumed Lupinepublishers-openaccess-ophthalmology-journal which is on the verge of thermal fluctuations Lupinepublishers-openaccess-ophthalmology-journal This means that a billion (109) transistor chip uses order energy in a single act 10-3J. Then, in order of speed 1GHz , the energy consumed can reach values Lupinepublishers-openaccess-ophthalmology-journal far exceeding the power of a jogging electric kettle Lupinepublishers-openaccess-ophthalmology-journal

In order to remove Joule-Lenz heat in electric nanoelements, both microchannels with liquid carriers of heat and conductive elements, such as nanocomposite ceramics filled with carbon nanotubes, can be used, which, depending on their chiral characteristics, can alter the physical properties of nano cells. Thus, it was established [9-12] and confirmed by theoretical estimates [13,14] that the thermal conductivity at room temperature of a carbon nanotube can reach values of Lupinepublishers-openaccess-ophthalmology-journal which significantly exceeds the thermal conductivity of diamon Lupinepublishers-openaccess-ophthalmology-journal which was considered one of the best heat conductors. Carbon nanotubes are thermally stable, characterized by high electrical conductivity [10], high electron mobility [11], and a large specific surface value [15]. It is believed [16] that the abnormally high thermal conductivity of carbon nanotubes is due to their regular structure and the small number of defects and impurity centers in them. In the elementary cell of graphene there are two carbon atoms, so the dispersion spectrum consists of three optical and three acoustic branches, among which the longitudinal and transverse acoustic modes correspond to the speed of sound 2130 and 1360 M/s



Read more about this article : https://lupinepublishers.com/ophthalmology-journal/fulltext/cauchy-modeling-as-a-new-trend-in-research-of-fullerene-type-nanomaterials.ID.000156.php

Read More About Lupine Google Scholar: https://scholar.google.com/citations?view_op=view_citation&hl=en&user=T4c9RDkAAAAJ&citation_for_view=T4c9RDkAAAAJ:M3NEmzRMIkIC

Thursday, July 27, 2023

A Review of Metabolic Sensors in Glaucoma

 

Abstract

Glaucoma is the second leading cause of irreversible blindness worldwide. It is a multifactorial, progressive, chronic optic neuropathy that is characterized by loss of retinal ganglion cells (RGC) and optic nerve head (ONH) cupping including extra cellular matrix (ECM) remodelling and fibrosis at the lamina cribrosa (LC). Clinically this results in chronic, progressive peripheral visual field loss. The pathogenesis of glaucoma is not yet fully understood. Therefore, there is an urgent need to identify and target the underlying mechanisms governing ECM remodelling of the LC, in order to stop the progressive, chronic damage to the LC/ONH and irreversible visual field loss. This review identifies and examines some of the key metabolic processes and cellular sensors involved in the pathogenesis of ECM fibrosis in general but herein specifically in glaucoma, including mitochondrial dysfunction and adenosine monophosphate activated protein kinase (AMPK) upregulation. Furthermore, the development of novel therapeutics such as nicotinamide (NAM) and metformin are discussed as promising potential future therapeutic options for glaucoma.

Read more about this article : https://lupinepublishers.com/ophthalmology-journal/fulltext/a-review-of-metabolic-sensors-in-glaucoma.ID.000155.php

Read More About Lupine Google Scholar: https://scholar.google.com/citations?view_op=view_citation&hl=en&user=T4c9RDkAAAAJ&citation_for_view=T4c9RDkAAAAJ:maZDTaKrznsC

Saturday, July 8, 2023

A Review of Achromatopsia

 

Abstract

Congenital achromatopsia is a hereditary form of day blindness caused by cone photoreceptor dysfunction, with an incidence of approximately 1 in 30,000. This inherited disorder is characterized by a lack of color discrimination, nystagmus, photophobia, and low visual acuity (< 0.2). The most typical genetic mutations are autosomal recessive changes in CNGA3, CNGB3, GNAT2, PDE6H, PDE6C, or ATF6. It should not be confused with cerebral achromatopsia, which is an acquired form of total color blindness that can result from illness, trauma, or some other cause. Color plays an essential role in our lives. It can change actions, influence thinking, and cause reactions. As a powerful type of communication, color is irreplaceable. Green means “go” and red means “stop”. Traffic lights send this global meaning. Color vision deficiency, creates challenges in the daily lives of those who have an insufficient visual sense.

Purpose: The aim of this review is to examine the literature published on achromatopsia and summarize the diagnosis, management, genetic characteristics, and the recent advances in gene therapy.

Conclusions: Congenital achromatopsia is a complex inherited disease. Management of achromatopsia is multifaceted. There is currently no cure for achromatopsia, although gene therapy is a therapeutic option already being studied in clinical trials. The most recent study in human adults can be classified as safe and positive in terms of efficacy.

Keywords: Achromatopsia (ACHM); Gene therapy

Introduction

Achromatopsia is a condition characterized by a partial or total absence of color vision [1]. People with complete achromatopsia cannot perceive any colors; they only see white, black, and shades of gray. Incomplete achromatopsia is a milder form of the disease that allows some color discrimination [1]. Oliver Sacks, in The Case of Color-blind Painter [2], transcribe the disturbing story of one of his cerebral achromatopsia patients after a car accident in the following way: Mr. I. could hardly tolerate the changed aspects of people (“like animated grey statues”) any more than he could tolerate his own appearance in the mirror: he shunned social intercourse and found sexual intercourse impossible. He saw people’s fesh, his wife’s fesh, his own fesh, as an abhorrent grey; “fesh-colored” now appeared “rat-colored” to him.


Read more about this article : https://lupinepublishers.com/ophthalmology-journal/fulltext/a-review-of-achromatopsia.ID.000154.php


Read More About Lupine Google Scholar: https://scholar.google.com/citations?view_op=view_citation&hl=en&user=T4c9RDkAAAAJ&citation_for_view=T4c9RDkAAAAJ:k_IJM867U9cC

Tuesday, June 27, 2023

Intravitreal Injection of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion

 

Abstract

Aim: This study aimed to evaluate the safety and efficacy of intravitreal Ranibizumab 0.5mg in the treatment of macular edema secondary to retinal vein occlusion.

Patients & Methods: This was a prospective interventional analytical study included 39 eyes of 39 patients with retinal vein occlusion. Ophthalmic examination included assessment of visual acuity, measurement of intraocular pressure, and fundus examination. All patients were scanned using Swept source optical coherence tomography (3D DRI OCT Triton [plus], Topcon Corporation, Tokyo, Japan) to assess central macular thickness. The changes of visual acuity, IOP, and central macular thickness were assessed. Data were analyzed via Kolmogorov-Smirnov test and Wilcoxon signed rank.

Results: The mean age was 56.56 ± 9.6, 48.7% were male and 51.3% were females. Hypertension was detected in 69.2%, and hyperlipidemia in 2.6%. The mean best corrected visual acuity was 1.5 logMAR, 1.00 logMAR,1.00 logMAR, preoperative, fourth month, six months postoperative, respectively, (p<0.001). The mean central macular thickness was 675 μ, 306 u, 264 u, preoperative, fourth month, six months postoperative, respectively, (p< 0.001). The OP was 16.5 mmHg, 16.9 mmHg, 17.1 mmHg, preoperative, fourth month, six months postoperative, respectively, (p=0.423). There were no observed significant ocular adverse events such as ocular inflammation, sterile and infectious endophthalmitis, or sustained increase in intraocular pressure with the use of intravitreal ranizumab injections.

Conclusion: Intravitreal Ranibizumab injections as monotherapy have shown promising results with BCVA improvement and a decrease of central macular thickness in patients with macular edema secondary to retinal vein occlusion.

Keywords: Ranibizumab; Macular Thickness; OCT; Visual Acuity

Introduction

Retinal vein occlusion (RVO) is the most common retinal vascular disease after diabetic retinopathy [1]. Depending on the area of retinal venous drainage effectively occluded it is broadly classified as either central retinal vein occlusion (CRVO), hemispheric retinal vein occlusion , or branch retinal vein occlusion (BRVO) [2]. Although the exact etiology of RVO remains elusive, it is likely to follow a thrombotic event. In CRVO this may occur in the central retinal vein (CRV) at the lamina cribrosa or at a variable distance in its journey within the optic nerve posterior to the lamina cribrosa [2]. Hypoxia-induced expression of vascular endothelial growth factor (VEGF) is thought to be a trigger for macular edema. High intravitreal levels of VEGF have been found in patients with retinal vein occlusion [3]. Upregulation of VEGF is associated with breakdown of the blood-retina barrier with increased vascular permeability resulting in retinal edema, stimulation of endothelial cell growth, and neovascularization [4,5]. Macular edema leads to vision loss in many patients with either central or branch retinal vein occlusions (CRVO or BRVO). BRVO is the more common of the two presentations, accounting for approximately 80% of RVO [6].
Recently, there has been interest in the use of vascular endothelial growth factor (VEGF) inhibition in the treatment of RVO because of the observation of increased VEGF in the vitreous and aqueous of patients with these conditions [7].

Read more about this article : https://lupinepublishers.com/ophthalmology-journal/fulltext/intravitreal-injection-of-ranibizumab-in-macular-edema-secondary-to-retinal-vein-occlusion.ID.000153.php


Read More About Lupine Google Scholar: https://scholar.google.com/citations?view_op=view_citation&hl=en&user=T4c9RDkAAAAJ&cstart=20&pagesize=80&citation_for_view=T4c9RDkAAAAJ:isC4tDSrTZIC

Tuesday, June 13, 2023

Visual Impairment and its Rehabilitation: A Review

 

Abstract

Visual impairment (VI) is a condition of reduced visual performance that cannot be remedied by refractive correction (spectacles or contact lenses), surgery or medical methods. Visual Impairment is a broader term that encompasses both Low vision and Blindness. The prevalence of visual impairment is estimated to be around 2.2 billion in the world as per World Health Organization (WHO). Causes of Visual Impairment differs significantly in different regions. Saying that, still cataract and refractive errors are main causes of visual impairment globally. Owing to its negative impact on the individual’s dailies, professional life, productive time, confidence, and self-respect, VI needs to be addressed timely and appropriately. Visual impairments do have profound consequences for the individual, however effective rehabilitation services can restore independence and therefore ameliorate these consequences and restore the individual’s quality of life.

Keywords: Visual Impairment; Blindness; low Vision; Rehabilitation; Optical Devices; Non-Optical Devices

Introduction

Impairment of any kind (sensorial or motor) is a bane for any human being. With visual impairment being one of the leading causes of sensorial impairment, it is necessary to acknowledge its prevalence, causes and methods to avoid them, if possible. Also, at the same time, it is important to understand that the term “visual impairment”, “blindness” and “Low vision” are not synonymous; rather visual impairment includes low vision as well as blindness. Simply, Visual impairment (VI) is a condition of reduced visual performance that cannot be remedied by refractive correction (spectacles or contact lenses), surgery or medical methods [1]. Various definitions of visual impairment have been given by various concerned authorities. International Statistical Classification of Diseases and Related Health Problems (ICD) defines visual impairment categories primarily on the basis of recommendations made by a World Health Organization (WHO) Study Group in 1972 [2] and defines as:

• low vision is defined as visual acuity of less than 6/18, but equal to or better than 3/60, or a corresponding visual field loss to less than 20 degrees in the better eye with best possible correction
• blindness is defined as visual acuity of less than 3/60, or a corresponding visual field loss to less than 10 degrees in the better eye with best possible correction.


Read more about this article : https://lupinepublishers.com/ophthalmology-journal/fulltext/visual-impairment-and-its-rehabilitation-a-review.ID.000152.php


Read More About Lupine Google Scholar: https://scholar.google.com/citations?view_op=view_citation&hl=en&user=T4c9RDkAAAAJ&citation_for_view=T4c9RDkAAAAJ:TFP_iSt0sucC

Multiple Focal Choroidal Excavations in Association with Protein Rich Diet

  Introduction Choroidal excavation is a novel entity that is diagnosed with optical coherence tomography (OCT). In 1959, Klien,...